Disturbance of HDL apolipoprotein AI metabolism in severe hyperlipidemic and lipodystrophic HIV patients on a protease inhibitor treatment

Khadija Ouguerram,Michel Krempf,Yassine Zair,Stéphanie Billon

doi:10.1186/1742-4690-7-s1-p90

Abstract

Methods Seven HIV infected patients, normolipidemic with no lipodystrophy (group A) and seven hyperlipidemic with lipodystrophy (group B) were studied. Patients are on protease inhibitors since at least six months. Patients were underwent in vivo kinetics of HDL-AI using a 14 h primed constant infusion of [5,5,5,H3] leucine. Kinetic data were analyzed by monocompartmental model using SAMII program to drive metabolic parameters (FCR, Fractional Catabolic Rate, and APR, Absolute Catabolic Rate).

Highlights

The aim of this study was to characterize the metabolic abnormalities resulting in low HDL apolipoprotein AI (HDL-AI) levels in lipodystrophy HIV infected patients during protease inhibitor therapy
HDL cholesterol and apolipoprotein AI were significantly (P < 0.05) lower in group B compared to group A
HDL are more enriched in triglycerides in group B compared to group A (P < 0.005)

Summary

Introduction

The aim of this study was to characterize the metabolic abnormalities resulting in low HDL apolipoprotein AI (HDL-AI) levels in lipodystrophy HIV infected patients during protease inhibitor therapy.to low absolute catabolic rate. Disturbance of HDL apolipoprotein AI metabolism in severe hyperlipidemic and lipodystrophic HIV patients on a protease inhibitor treatment Khadija Ouguerram*, Yassine Zair, Stéphanie Billon, Michel krempf From 16th International Symposium on HIV and Emerging Infectious Diseases Marseille, France.

Objectives

Results

Conclusion